Tenax Therapeutics TENX Insider Ownership

Updated Oct 11, 2026

Over the past year, TENX insiders bought $5.12 million of stock (2.79Mn shares) on the open market and sold none.

• Behind Tenax Therapeutics' open-market purchases in the past 12 months were 7 insiders, and no insider sold.
• Among Tenax Therapeutics' insiders, the largest open-market purchases in the past 12 months were by Adar1 Capital Management, LLC (10% owner), totaling $4.8 million (2.7Mn shares), most recently on September 3, 2026.
• Tenax Therapeutics' latest insider trade on the open market was a purchase of 53K shares for $101,760 by Declan Doogan (Director) on September 16, 2026.
• Apart from open-market trades, TENX insiders received 10K shares in stock awards and acquired 8.72K shares through option exercises and conversions in the past 12 months.
• According to Business Quant data, insiders at Tenax Therapeutics reported 6.65Mn shares in total in their latest Form 4 filings.
• Direct holdings account for 106.93K shares (1.61%) of TENX's insider total, and indirect holdings through trusts, partnerships and family members for 6.54Mn shares (98.39%).
• TENX's insider total is spread across 9 insiders who have filed a Form 4 in the past two years.
• Tenax Therapeutics' three biggest insider holders are Adar1 Capital Management, LLC (10% owner, 6.52Mn shares), Declan Doogan (Director, 55.27K shares) and Christopher Thomas Giordano (CEO, 22.17K shares), based on their latest Form 4 filings.
• Of the shares held by TENX insiders, 98.16% belong to Adar1 Capital Management, LLC.
• Institutions accounted for 59.64% of TENX's outstanding shares in Q2 2026, insiders about 13.07% per their latest Form 4 filings, and other investors, including the public, about 27.29%.
• A total of 22 Form 4 filings with transactions in Tenax Therapeutics stock were made over the past 12 months, by 10 insiders.
• These insider figures for Tenax Therapeutics are based on Form 4 filings through September 17, 2026.